+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Susan M. Greenwood | Bloomberg Law Silverstrand Investments v. AMAG Pharaceuticals, Inc., No. 10-CV-10470, 2011 BL 208853 (D. Mass. Aug. 11, 2011) The U.S. District Court for the District of Massachusetts dismissed plaintiffs' claims under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 against AMAG Pharmaceuticals, Inc. (AMAG), certain of its officers and directors, and its underwriters (collectively, Defendants), concerning AMAG's January 21, 2010 secondary offering of securities (Offering). The Court held that Defendants had no duty to disclose certain information concerning AMAG's intravenous iron-replacement drug, Feraheme, under Items 303(a)(3)(ii) or 503(c) of Securities and Exchange Commission Regulation S-K. Plaintiffs alleged that Defendants failed to disclose (1) 23 post-marketing reports of serious adverse events (SAEs) related to Feraheme, (2) that the Food and Drug Administration (FDA) declined to approve Feraheme twice due to safety concerns, and (3) that AMAG allegedly derived its revenue from illegal marketing practices. The Court held that the "mere existence of reports of SAEs is insufficient" to require disclosure under Item 303. Moreover, the Court noted that the SAEs "were consistent with the previously and publicly-disclosed rates [of adverse reactions] observed in the clinical trial" and, thus, "did not constitute a known trend that would have a material unfavorable impact on sales, revenue or income." Similarly, Defendants' risk disclosures in the Offering documents, "including data from the clinical trials and how SAEs could impact Feraheme's success," met Item 503's requirement to disclose significant risk factors. The Court also held that Defendants were not required to disclose AMAG's failed attempts to win FDA approval of Feraheme or the agency's Warning Letter on AMAG's marketing practices. According to the Court, "the FDA's subsequent approval of [Feraheme] prior to the Offering indicates any concerns raised previously . . . had been resolved." In addition, the Court said, there was no duty to disclose Feraheme's failed applications because the FDA already had disclosed publicly the outcome of those applications. Finally, as to the FDA Warning Letter, the Court explained that AMAG received the letter months after the Offering. "[T]he Court 'may not employ 20/20 hindsight' but rather must consider whether the omission was material on the date the Offering Documents were issued." Plaintiffs did not "establish any connection between the Warning Letter or the allegations contained [in the complaint] and the time of the Offering."
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).